secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001640334-23-000833
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.0
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria engages InClin as CRO for Phase 1b hypertension study; budget $1.4M
---------------------------------------------------------------------------

- Master Services Agreement with InClin for FDA-registered Phase 1b hypertension study HYPER-H23-1 using DehydraTECH-powered cannabidiol.
- Initial work order budget $1,395,000; includes $72,355 (10% direct costs) and $335,242 (50% pass-through costs).
- Financing of at least US$1,000,000 completed, making the work order definitive.
- Both MSA and work order can be terminated with or without cause on 30 days' notice.
- Kick-off meeting between Lexaria and InClin scheduled for late May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423000833/0001640334-23-000833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423000833/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-23-000833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer